



REQUEST FOR
PROPOSALS

THERAPY DE-ESCALATION IN PEDIATRIC NEURO-ONCOLOGY

The **Rising Tide Foundation for Clinical Cancer Research** is excited to announce the opportunity for funding interventional clinical trials **on therapy de-escalation in pediatric neuro-oncology** with the aim to reduce both short- and long-term treatment-associated toxicity.

There is a critical unmet need to reduce the burden of toxicity caused by current practice use of therapeutic agents while maintaining efficacy. This request for proposals (RFP) welcome trials focused on therapy toxicity de-escalation in all types of pediatric central nervous system tumors, such as changing the administration schedule, de-escalating surgery, or radiotherapy, decreasing the dose or changing the combination therapy. Some examples of de-escalation are targeted therapy (such as MEK inhibitor) in low-grade gliomas, vincristine, steroid use for side effect management.

We encourage clinical trials that include measurements of biomarkers / biological features to correlate de-escalation while maintaining efficacy, as well as those that measure special adverse effects to determine potential improvement in toxicity, such as patient-reported or neurologic outcomes. Phase I, II or multicenter phase III clinical trials are strongly recommended.

The total budget for this RFP is **USD 2 million**. The amount allocated per grant will depend on the number of applications selected for funding. Further details can be found at <http://www.risingtide-foundation.org/clinical-cancer-research-pediatric-neuro-oncology>

LOI Application Deadline: 11 December 2023, 23:59 CET

To apply please follow the instructions on our website [how to apply](#). Interested applicants are encouraged to contact the team at rtfccrteam@risingtide.ch for further information about the RFP.